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 SYMPOSIUM: OPTIMISATION IN PROSTATE RADIO-
THERAPY – WHERE DO WE PUT OUR MONEY?  
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The main goal of research in the field of radiotherapy (RT) is to 
achieve maximum tumor control while sparing normal tissues. For this 
reason, reducing the uncertainties associated with treatment delivery 
is essential, as they affect the entire therapeutic process. 
Clinical uncertainties: The first uncertainty associated with RT is the 
need to deliver RT to patients with low-very-low risk disease and after 
surgery, i.e. to avoid excess RT in patients with clinically insignificant 
prostate cancer or in post-prostatectomy patients. Once an indication 
for RT is established, it is important to (1) identify the targets, (2) 
select neo-adjuvant and/or adjuvant therapies, and (3) select the 
total dose and daily fraction. Clinicians often overlook these factors as 
sources of uncertainty. For this reason, one of the major goals of 
future RT procedures and technologies should be to reduce the uncer-
tainty of identifying the extent and location of the tumor, and the 
potential radiosensitivity of the cancer cells and normal tissues. 
Further studies are needed to determine whether the prescribed dose 
levels might differ among various prognostic groups, if non-
homogeneous dose distributions are preferable for different radiosen-
sitive regions in the prostate, or if selective dose de-escalation is 
feasible in selected patients. 
Technical uncertainties: In the current scenario, any attempts to 
reduce the uncertainty of target localization for treatment delivery 
are well justified. Image-guided RT techniques allow the radiation 
oncologist to accurately localize the target tissue, which limits the 
uncertainty associated with setup errors, organ shape/filling (or 
voiding) variations, and inter-fraction organ movement. Accurate 
localization of the target helps to reduce the planned target volume 
(PTV) margins around the clinical target volume (CTV), to include a 
smaller volume of the rectum/bladder in the high-dose region, and to 
decrease the dose absorbed by the patient.These factors help to 
reduce the incidence of late RT-induced toxicities. 
To prevent target missing due to intra-fraction movements, several 
recent studies focused on four-dimensional RT, which improved the 
localization accuracy in all four dimensions (space+time).  
Extreme reduction of the CTV margins and further research to im-
prove existing technologies are expensive. For this reason, the clinical 
advantages, if any, of the dosimetric gains in the organs at risk must 
be determined. It must also be examined whether the margin reduc-
tions are beneficial for all patients or for selected patients, such as 
those harboring known clinical/geneticrisk factors. 
Patient-related uncertainties: The considerations described above 
have opened another major research field: the issue of reducing 
uncertainties in RT delivery while considering the cost of using these 
sophisticated techniques. We should encourage widespread collection 
of clinical data in relation to tumor control and RT-induced toxicity, 
ideally for all treated patients, and invest in data warehousing, data 
mining,and statistical analysis. Currently, <5% of patients are partici-
pating in clinical trials, so most patients could be included in such 
data collection. Increasing the number of databases focusing on 
patient factors, disease characteristics, and treatment options, will 
facilitate individualized and real-time prediction of desired outcomes. 
Availability of such databases, that allow the clinician to choose an 
optimal treatment based on known patient’s factors, might have 
significant advantages over existing prediction tools: similar patients 
can be grouped and easily found, with predictions updated in real 
time, overcoming the limitation of patient variability (e.g., stage 
migration) and changes in treatment options over time. 
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Up to 40% of patients with intermediate-risk prostate cancer will fail 
radical prostatectomy or precision image-guided radiotherapy (IGRT). 
Additional genetic prognosticators are needed to triage these patients 
towards intensified combination therapy with novel targeted thera-
peutics to improve both local and systemic control rates.  To address 
these questions, we are performing genomic analyses (for mutations 
and copy number alterations (CNAs) using comparative genomic 
hybridization and whole genome sequencing) of tumour DNA derived 
from frozen needle biopsies of 126 men with intermediate-risk disease 
who underwent image-guided radiotherapy (IGRT) to a mean dose of 
76.4Gy or men undergoing radical prostatectomy.   
Patients whose tumors had CNAs in both PTEN and c-MYC, NKX3.1 and 
StAR/HSD17B2 had significantly increased genetic instability (percent 
genome alteration; PGA).  We demonstrate that c-MYC gain alone, or 
combined c-MYC gain and PTEN loss, were increasingly prognostic for 
relapse on multivariable analyses (hazard ratios (HR) of 2.58/p=0.005 
and 3.21/p=0.0004; respectively).  Other loci were also prognostic for 
biochemical disease-free relapse (StAR: HR=2.84, 95% CI: 1.44-5.61, 
p=0.00269; HSD17B2: HR=1.97, 95% CI: 1.06-3.64, p=0.031 and, 
NKX3.1 haploinsufficiency was associated with bRFR when tested 
alone (HR=3.05, 95% CI:1.46-6.39, p=0.0030) or when combined with 
c-MYC gain (HR=3.88, 95% CI:1.78-8.49, p=0.00067)). All aCGH hits 
were also positive for outcome on multivariate analyses in prostate 
cancer surgery patients. 
Finally, a novel genetics-based signature has been developed that is 
independently prognostic. Our multidisciplinary group has also shown 
that both increased genetic instability and intra-glandular hypoxia 
predicts for poor outcome in intermediate risk prostate cancer. 
Additionally, when paired with information from hypoxia measure-
ments in the same patients, a combination of genetic and hypoxic 
biomarkers is more prognostic that either alone. 
Our data from primary human specimens suggest that triaging patients 
by the use of personalized genetics may allow for better use of sys-
temic therapies to target sub-clinical metastases or locally recurrent 
disease. The development and utility of such genetics-based tests and 
use within novel clincal trials with curative intent will be discussed. 
This personalized approach will improve clinical outcome in more than 
20,000 patients worldwide who currently fail precision radiotherapy 
and surgery despite having localized disease. 
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Stereotactic body radiotherapy has previously been successfully used 
in the treatment of metastatic lesions located in the lung and liver. It 
could also be considered as a curative option for patients suffering 
from oligometastases. In our Department, the feasibility, efficacy, 
and toxicity of SBRT as been evaluated for treatment of unresectable 
hepatic or lung metastases regardless of their primary tumor site for 
patients with a history of agressive systemic chemotherapy. Between 
July 2007 and June 2010, 90 patients were prospectively enrolled in 
this observational study and treated with the SBRT for hepatic or 
pulmonary metastatic lesions. A total of 113 liver and 26 lung metas-
tatic lesions in 52 men (58%) and 38 women (42%) were treated. Local 
control rates at 1 and 2 years were 84.5% and 66.1%, respectively. 
Two-year overall survival rate was 70% (95% CI: 55–81%) and the 1 and 
2-year disease-free survival rates were 27% (95% CI: 18–37%) and 10% 
(95% CI: 4–20%).  
Such results suggest that SBRT could be an effective treatment option 
extending patients’ life span with good quality of life following treat-
ment. Overall survival is comparable with other available techniques. 
Treatment is well tolerated with very low toxicity. This treatment 
modality appears to be more effective when used prior to the initia-
tion of systemic treatment regimens,which can be an important 
finding to be tested further. It could represent an interesting treat-
ment option for oligometastatic patients not amenable to surgery, 
even when patients had been heavily pre-treated with chemotherapy. 
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